Pfizer's Macugen Demonstrates Prolonged Safety Profile
Posted on: Monday, 20 February 2006, 12:00 CST
In a two-year review of safety data from a trial evaluating Pfizer's wet AMD medication Macugen, the VEGF inhibitor was not associated with an increased risk of cardiovascular adverse events such as blood clots, excessive bleeding or hypertension.
Such adverse events have been reported in cancer patients receiving systemic administration of a pan-VEGF inhibitor, with a greater incidence in patients over 65 years of age.
"The two-year systemic safety of Macugen is particularly reassuring because wet AMD usually afflicts people over the age of 65, an age group already at increased risk of cardiovascular disease, including heart disease and stroke," said Professor Marcos Avila, Universidade Federal de Goias, Goias, Brazil.
A separate review of the data found no new eye-related safety concerns with continuous Macugen treatment for more than one year. These data were presented at the World Ophthalmology Congress in Sao Paolo, Brazil.
Macugen is the only VEGF inhibitor with reported two-year safety data in wet AMD, and the only VEGF inhibitor that specifically targets VEGF165, the isoform primarily responsible for promoting the blood vessel growth and leakage associated with wet AMD.
Source: Datamonitor
Related Articles
- FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case
- Allos Therapeutics Reports Interim Response and Safety Data From Pivotal Phase 2 PROPEL Trial
- MacuSight Reports Positive Results of Phase I Wet AMD Study
- VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
- Kosan Presents Encouraging Antitumor and Safety Data on Novel Epothilone KOS-1584 at EORTC
- Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
- Genentech Eye Injection Effective Against Wet AMD
- Isotechnika Reports Positive Safety Data for Psoriasis Drug
- LOUISIANA: S&U Tax: Exemption for Sales of VEGF Inhibitors Enacted
- New REMICADE Safety Data Presented at the American College of Gastroenterology Annual Meeting
 |
 |
User Comments (0)
RSS Feeds